GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » ROA %

ZELTIQ Aesthetics (ZELTIQ Aesthetics) ROA % : 20.06% (As of Dec. 2016)


View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ZELTIQ Aesthetics's annualized Net Income for the quarter that ended in Dec. 2016 was $41.1 Mil. ZELTIQ Aesthetics's average Total Assets over the quarter that ended in Dec. 2016 was $205.0 Mil. Therefore, ZELTIQ Aesthetics's annualized ROA % for the quarter that ended in Dec. 2016 was 20.06%.

The historical rank and industry rank for ZELTIQ Aesthetics's ROA % or its related term are showing as below:

ZLTQ's ROA % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -1.93
* Ranked among companies with meaningful ROA % only.

ZELTIQ Aesthetics ROA % Historical Data

The historical data trend for ZELTIQ Aesthetics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZELTIQ Aesthetics ROA % Chart

ZELTIQ Aesthetics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
ROA %
Get a 7-Day Free Trial -30.72 -21.65 1.60 29.57 0.35

ZELTIQ Aesthetics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.68 -22.48 -10.92 10.86 20.06

Competitive Comparison of ZELTIQ Aesthetics's ROA %

For the Medical Devices subindustry, ZELTIQ Aesthetics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZELTIQ Aesthetics's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's ROA % distribution charts can be found below:

* The bar in red indicates where ZELTIQ Aesthetics's ROA % falls into.



ZELTIQ Aesthetics ROA % Calculation

ZELTIQ Aesthetics's annualized ROA % for the fiscal year that ended in Dec. 2016 is calculated as:

ROA %=Net Income (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=0.694/( (178.827+214.345)/ 2 )
=0.694/196.586
=0.35 %

ZELTIQ Aesthetics's annualized ROA % for the quarter that ended in Dec. 2016 is calculated as:

ROA %=Net Income (Q: Dec. 2016 )/( (Total Assets (Q: Sep. 2016 )+Total Assets (Q: Dec. 2016 ))/ count )
=41.108/( (195.557+214.345)/ 2 )
=41.108/204.951
=20.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2016) net income data. ROA % is displayed in the 30-year financial page.


ZELTIQ Aesthetics  (NAS:ZLTQ) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2016 )
=Net Income/Total Assets
=41.108/204.951
=(Net Income / Revenue)*(Revenue / Total Assets)
=(41.108 / 420.44)*(420.44 / 204.951)
=Net Margin %*Asset Turnover
=9.78 %*2.0514
=20.06 %

Note: The Net Income data used here is four times the quarterly (Dec. 2016) net income data. The Revenue data used here is four times the quarterly (Dec. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ZELTIQ Aesthetics ROA % Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Traded in Other Exchanges
N/A
Address
ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
Executives
Todd Erik Zavodnick officer: President, International C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser officer: SVP, Research and Development C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison officer: SVP of Global Marketing C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley director, officer: President and CEO ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris officer: SVP & Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman director
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan officer: CCO, President, North America C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams officer: SVP & CFO C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis officer: Chief Technical Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines